Oximunol Chewable Tablets draw veterinarians from across Canada to Avivagen Animal Health booth at Canadian Veterinary Medical Association (CVMA) Convention


Chemaphor subsidiary Avivagen Animal Health's products reach over 400 Canadian veterinarians at another successful tradeshow

OTTAWA, ONTARIO, August 9, 2011 - Traffic was heavy at the Avivagen Animal Health booth at the CVMA convention in Halifax, N. S. as many veterinarians from across Canada got their first opportunity to talk one-on-one with company representatives about new Oximunol(TM) Chewable Tablets and VetStem RC Regenerative Cell Therapy.

"We had a lot of vets seek us out to learn more about our products," says Dave Hankinson, CEO of Avivagen Animal Health. "They told us they had seen our advertising for Oximunol Chewable Tablets and VetStem RC Regenerative Cell Therapy and wanted to learn more. This was the first opportunity we have had to talk to many of these vets in person so it was a very successful show."

"I can see a fit for Oximunol Chewable Tablets in my practice for older dogs with arthritis and dogs with coat and skin problems," says Dr. Peggy Taylor-Mason, veterinarian with the Cypress View Veterinary Clinic in Medicine Hat, Alta. "Many of my clients like the idea of more natural alternatives to treat their pets for various conditions."

"I have got a few dogs on Oximunol Chewable Tablets for skin and mobility issues," says Dr. Morris Belanger, veterinarian with Manitoba Road Animal Hospital in Elliot Lake, Ont. "With my own dog, a Yorkshire Terrier, I have seen improvement in the lustre and quality of its coat."

The CVMA Convention was the fourth tradeshow Avivagen has participated in this year. Later this year, Avivagen Animal Health will exhibit at the Animal Health Technologists Association of British Columbia Conference in Kamloops, B.C. and the CanWest Veterinary Conference in Banff, Alta.

Oximunol Chewable Tablets contain OxC-beta, a fully oxidized form of ss-carotene, that is made up of compounds occurring naturally in the plant world. These compounds offer significant health benefits to dogs, including improved skin and coat and increased mobility, in a palatable, chewable daily tablet.

VetStem RC Regenerative Cell Therapy is scientifically proven for treatment of arthritic conditions, and joint and ligament injuries in dogs, cats and horses. The therapy uses regenerative cells derived from an animal's own fat tissue.

Avivagen is a new Canadian company dedicated to improving the quality of life of animals through science-based, natural health products proven in clinical trials and sold exclusively through veterinarians. Avivagen is a subsidiary of Chemaphor Inc., a Canadian company dedicated to the research and development of science-based, natural products for people and animals. VetStem RC Regenerative Cell Therapy has been exclusively licensed by Avivagen for the Canadian animal health market from Vet-Stem (USA).

Chemaphor is listed on the TSX Venture Exchange and trades under the symbol CFR.

###

For more information:

David Hankinson Graham Burton, PhD CEO, Avivagen Animal Health Inc. President and Co-Founder, Chemaphor Inc. Phone: 902-825-9270 Phone: 613-990-0969 d.hankinson@chemaphor.com g.burton@chemaphor.com

Investor Relations: Media Group:

Evolution Group Inc. McCormick Global Communications Sylvain Archambault Karen Sample 514-448-4887 / Toll free: 866-703-4887 Phone: 519-475-6378 s.archambault@evolutiongrp.com ksample@mccormickglobal.com www.evolutiongrp.com

TM Trademark of Chemaphor Inc. VetStem RC Regenerative Cell Therapy is licensed from Vet-Stem, Inc.

Forward Looking Statements This news release includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with the business of Chemaphor Inc. and Avivagen Animal Health Inc. and the environment in which their respective businesses operate. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions. The forward-looking statements reflect the current expectations of Chemaphor Inc. and Avivagen Animal Health Inc. regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Chemaphor assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements. The results of treatment described above are based on historical results. Different animals may experience different results from the treatments described above. Anyone interested in the treatments described above should discuss the potential benefits and risks of such treatments with their veterinarian. The interest expressed by Conference attendees and the leads described above may not translate into orders for products.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.